57452-31-0

Basic information

• Product Name: (+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one
• Synonyms: (.+-)-2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1a)isoquinolin-4-one
• CAS NO: 57452-31-0
• Molecular Formula: C₁₉H₂₄N₂O₂
• Molecular Weight: 312.4061
• EINECS: 260-741-2
• Mol File: 57452-31-0.mol
• Article Data: 52

Chemical Properties

• Boiling Point: 544.1°C at 760 mmHg
• Flash Point: 254.6°C
• Density: 1.22g/cm³
• Vapor Pressure: 6.71E-12mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: (+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one(57452-31-0)
• EPA Substance Registry System: (+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one(57452-31-0)

Safety Data

• Hazardous Substances Data: 57452-31-0(Hazardous Substances Data)

Usage

Description

(+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one is a heterocyclic compound with a hexahydro-4H-pyrazino-isoquinolinone structure. It is a derivative of pyrazinoisoquinoline and contains a cyclohexylcarbonyl group. (+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one has potential pharmaceutical applications and may be used in the development of medications for various conditions. Further research is needed to fully understand its properties and potential uses.

Uses

Used in Pharmaceutical Industry:
(+-)-2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1a]isoquinolin-4-one is used as a pharmaceutical compound for its potential applications in the development of medications for various conditions. Its unique structure and properties make it a promising candidate for further research and development in the pharmaceutical field.

Upstream product

• 79848-93-4 N-(1,2,3,4-tetrahydroisoquinolin-1-ylmethyl)cyclohexanecarboxylic acid amide 
• 79-04-9 chloroacetyl chloride 
• 60567-53-5 1-Cyclohexylcarbonylaminomethyl-2-chloracetyl-1,2,3,4-tetrahydro-isochinolin 
• 93255-08-4 Cyclohexanecarboxylic acid bicyclo[4.2.0]octa-1,3,5-trien-7-ylmethyl-[(methoxymethyl-carbamoyl)-methyl]-amide 
• 87693-75-2 4-(cyclohexylcarbonyl)-6-hydroxy-1-phenethylpiperazine-2-one 
• 94494-35-6 4-(cyclohexylcarbonyl)-3,4-dihydro-1-(2-phenylethyl)-2(1H)-pyrazinone 
• 152189-66-7 N-(2-phenylethyl)-N-(cyanomethyl)amide of cyclohexylcarbonylglycine 
• 2719-27-9 cyclohexanylcarbonyl chloride 
• 61196-37-0 2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one 
• 90142-13-5 N-(2,2-dimethoxyethyl)-N-(2-oxo-2-(2-phenethylamino)-ethyl)cyclohexanecarboxamide 
• 97004-08-5 N-(2,2-diethoxy)ethyl-N-2-phenylethyl 2-N-cyclohexylcarbonylaminoacetamide 
• 406954-89-0 1-[2-(2-bromophenyl)ethyl]-4-(cyclohexylcarbonyl)-1,3,4-trihydropyrazin-2-one 
• 32377-88-1 (cyclohexanecarbonyl-amino)-acetic acid 
• 65185-58-2 2-(2-bromophenyl)ethanamine 

Downstream Products

• 134924-71-3 2-(4-trans-hydroxycyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 134924-68-8 2-(4-cis-hydroxycyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 1609979-51-2 C₂₃H₂₃N₃O₂ 
• 1609979-52-3 C₃₄H₄₀N₆O₄ 
• 99746-73-3 (S)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 55375-92-3 (R)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one 
• 135526-78-2 (-)-Praziquantel 
• 57452-97-8 (+)-Praziquantel 
• 1609986-43-7 C₁₉H₁₇N₃O₄ 
• 1609986-44-8 C₁₉H₁₉N₃O₂ 
• 1609979-49-8 C₂₈H₂₂F₃N₅O₃ 
• 1609979-50-1 C₃₁H₂₄F₃N₅O₃ 
• 57452-32-1 2-(4-oxocyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 
• 57452-32-1 (-)-2-(4-oxocyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino<2,1-a>isoquinolin-4-one 

Relevant articles and documents

Synthesis and chiral recognition ability of a poly(phenylenevinylene)- encapsulated amylose derivative

Poly(p-phenylenevinylene) (PPV) was found to be encapsulated in amylose during the polymerization of the precursor monomer in an aqueous solution. The resulting amylosePPV composite can be further chemically modified by introducing various substituents in

A Nickel(II)-Mediated Thiocarbonylation Strategy for Carbon Isotope Labeling of Aliphatic Carboxamides

A series of pharmaceutically relevant small molecules and biopharmaceuticals bearing aliphatic carboxamides have been successfully labeled with carbon-13. Key to the success of this novel carbon isotope labeling technique is the observation that 13C-labeled NiII-acyl complexes, formed from a 13CO insertion step with NiII-alkyl intermediates, rapidly react in less than one minute with 2,2’-dipyridyl disulfide to quantitatively form the corresponding 2-pyridyl thioesters. Either the use of 13C-SilaCOgen or 13C-COgen allows for the stoichiometric addition of isotopically labeled carbon monoxide. Subsequent one-pot acylation of a series of structurally diverse amines provides the desired 13C-labeled carboxamides in good yields. A single electron transfer pathway is proposed between the NiII-acyl complexes and the disulfide providing a reactive NiIII-acyl sulfide intermediate, which rapidly undergoes reductive elimination to the desired thioester. By further optimization of the reaction parameters, reaction times down to only 11 min were identified, opening up the possibility of exploring this chemistry for carbon-11 isotope labeling. Finally, this isotope labeling strategy could be adapted to the synthesis of 13C-labeled liraglutide and insulin degludec, representing two antidiabetic drugs.

Two approaches for the synthesis of levo-praziquantel

We report herein the development of two pathways for the preparation of levo-praziquantel (R-PZQ), which involves three-/four-step processes of a mechanochemical (asymmetric) aza-Henry/acylation reaction, a hydrogenation reaction, (chiral resolution) and a solvent-free acylation-ring closing reaction. The key intermediate (R)-1-aminomethyl tetrahydroisoquinoline could be obtained either by chiral resolution with a rational reuse of the S-isomer or by mechanochemical enantioselective synthesis that refrained from using a bulky toxic solvent. The efficiency and scalability of both the developed routes were demonstrated and desired target product was obtained in a satisfactory yield with excellent enantiopurity (>99%), offering practical, concise and environmentally friendly alternatives to access R-PZQ.